An Epidemiologic Study of Depressive Symptoms among Cardiometabolic Department Patients in México
- 1
- 2
- 3
Abstract
Background. This study estimated the prevalence of depressive symptoms among cardiometabolic department patients in México. Methods. To identify patients with depressive symptoms, we used the Beck’s Depression Inventory (BDI). We analyzed data from consecutive adult patients who attended during a year to a Cardiometabolic Department in México and described the demographic, metabolic and vascular status differences between depressive and non-depressive patients. The estimates are based on a total of 180 patients aged 22 to 83 years. Results. There was a depressive symptoms prevalence rate of 60.5%. Compared with non-depressive patients, depressive patients were more likely to be obese, and to have dysglucemia, hypercholesterolemia, hypoalphalipoproteinemia, microalbuminuria, high uric acid levels, carotid atherosclerosis, insulin resistance and metabolic syndrome. Conclusions. Our data suggest that prevalence of depression is elevated among cardiometabolic patients in México. Depression probably plays a role in cardiometabolic physiopathogenic, and must be intentionally assessed in cardiometabolic patients in order to treat it and to improve the cardiometabolic treatment response and adherence.
- [1] M. E. Medina-Mora, G. Borges, C. Lara Mu?oz, C. Benjet, J. Blanco Jaimes, C. Fleiz Bautista, J. Villatoro Velázquez, E. Rojas Guiot, J. Zambrano Ruíz, L. Casanova Rodas, S. Aguilar-Gaxiola “Prevalencia de Trastornos Mentales y Uso de Servicios: Resultados de la Encuesta Nacional de Epidemiología Psiquiátrica en México,” Salud Mental, Vol. 26, No. 4, 2003, pp. 1-16.
- [2] L M. Bello, E. Puentes-Rosas, M. E. Medina-Mora and R. Lozano, “Prevalencia y Diagnóstico de Depresión en Población Adulta en México,” Salud Pública Mexico, Vol. 47, Suppl. 1, 2005, pp. S4-S11.
- [3] Téllez Zenteno José Francisco, Morales Buenrostro Luís Eduardo, H. Cardiel Mario, “Frecuencia y Factores de Riesgo Para Depresión en Pacientes con Diabetes Mellitus Tipo 2 en un Hospital de Tercer Nivel de Atención,” Medicina Interna de México Marzo, Vol. 17, No. 2, 2001, pp. 54-62.
- [4] S. M. López, H. Alveano and J. Carranza “Prevalencia de Síntomas Depresivos en Síndrome Metabólico,” Revista Facultad Nacional de Salud Pública, Vol. 26, No. 2, 2008, pp. 124-133.
- [5] S. Bonicatto, A. M. Dew and J. J. Soria, “Analysis of the Psychometric Properties of the Spanish Version of the Beck Depression Inventory in Argentina,” Psychiatry Research, Vol. 79, 1998, pp. 277-285. doi:10.1016/S0165-1781(98)00047-X
- [6] R. C. Arnau, M. W. Meagher, M. P. Norris and R. Bram-son “Psychometric Evaluation of the Beck Depression Inventory-II with Primary Care Medical Patients,” Health Psychology, Vol. 20, No. 2, 2001, pp. 112-119. doi:10.1037/0278-6133.20.2.112
- [7] L. K. Sharp and M. S. Lipsky, “Screening for Depression Across the Lifespan: A Review of Measures for Use in Primary Care Settings,” American Family Physician, Vol. 66, No. 6, 2002, pp. 1001-1009.
- [8] E. Bonora, G. Formentini, F. Calcaterra, S. Lombardi, F. Marini, L. Zenari, et al. “HOMA-Estimated Insulin Re-sistance is an Independent Predictor of Cardiovascular Disease in Type 2 Diabetic Subjects: Prospective Data from the Verona Diabetes Complications Study,” Diabetes Care, Vol. 25, No. 7, 2002, pp. 1135-1141. doi:10.2337/diacare.25.7.1135
- [9] W. T. Friedewald, R. I. Levy and D. S. Fredrickson “Es-timation of the Concentration of Low-Density Lipopro-tein Cholesterol in Plasma, without Use of Preparative Ultracentrifuge,” Clinical Chemistry, Vol. 18, No. 6, 1972, pp. 499-502.
- [10] K. Al-Shali, A. A House, A. J. Hanley, HM Khan, S. B. Harris, M. Mamakeesick, et al., “Differences between Carotid Wall Morphological Phenotypes Measured by Ultrasound in One, Two and Three Dimensions,” Atherosclerosis, Vol. 178, No. 2, 2005, pp. 319-325. doi:10.1016/j.atherosclerosis.2004.08.016